Abstract
The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acetanilides
-
Angina Pectoris / drug therapy*
-
Angina Pectoris / metabolism*
-
Angina Pectoris / nursing
-
Calcium Channel Blockers / metabolism
-
Calcium Channel Blockers / therapeutic use
-
Cardiovascular Agents / metabolism
-
Cardiovascular Agents / therapeutic use
-
Carnitine O-Palmitoyltransferase / antagonists & inhibitors
-
Drug Monitoring
-
Epoxy Compounds / therapeutic use
-
Fatty Acids / metabolism
-
Half-Life
-
Humans
-
Metabolic Clearance Rate
-
Nurse's Role
-
Nursing Assessment
-
Patient Education as Topic
-
Patient Selection
-
Perhexiline / analogs & derivatives*
-
Perhexiline / metabolism
-
Perhexiline / pharmacology
-
Perhexiline / therapeutic use
-
Piperazines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Ranolazine
-
Treatment Outcome
-
Trimetazidine / therapeutic use
-
Vasodilator Agents / metabolism
-
Vasodilator Agents / therapeutic use
Substances
-
Acetanilides
-
Calcium Channel Blockers
-
Cardiovascular Agents
-
Epoxy Compounds
-
Fatty Acids
-
Piperazines
-
Vasodilator Agents
-
Ranolazine
-
Carnitine O-Palmitoyltransferase
-
perhexiline maleate
-
Perhexiline
-
etomoxir
-
Trimetazidine